Literature DB >> 11978777

Functional modulation of expanded CD8+ synovial fluid T cells by NK cell receptor expression in HLA-B27-associated reactive arthritis.

Nicolas Dulphy1, Claire Rabian, Corinne Douay, Odile Flinois, Saddek Laoussadi, Jens Kuipers, Ryad Tamouza, Dominique Charron, Antoine Toubert.   

Abstract

The aim of this study was to determine whether NK cell receptor (NKR) expression could modulate cytotoxicity of oligoclonal CD8+ T cells present in the synovial fluid (SF) of HLA-B27-reactive arthritis (ReA) patients, especially in a TCRBV1 population shared among different patients and cytotoxic toward HLA-B27. A CD8+ T cell line, two TCRBV1 lines and clones were isolated from the SF of an HLA-B27+ ReA patient, and tested with mAb specific for Ig-like (KIR2DL1, KIR2DL2, KIR3DL1 and ILT2) and CD94 C-type lectin NKR. Transcripts for NKG2 subunits (NKG2A-2E) associated with CD94 were also evaluated. Function was tested in a 51Cr-release cytotoxic assay. We found stable but distinct levels of CD94/NKG2 complexes at the surface of T cell lines and clones. Different NKG2 members could be associated with CD94, either inhibitory (NKG2A/B) or activating (NKG2C). The inhibitory ILT2 receptor could also be differently expressed, but other Ig-like NKR were negative. Functionally, one TCRBV1 line and clones with a high CD94/NKG2A expression did not lyse B27+ targets. Another TCRBV1 line with the same TCRBV1 rearrangement had a low expression of CD94/NKG2A, but expressed NKG2C transcripts and was cytotoxic toward HLA-B27. HLA-B27 is a ligand for ILT2 and we observed an inhibitory effect of ILT2 engagement on B*2705 targets in blockade experiments. Altogether, these data indicate a high degree of heterogeneity in the expression of NKR by intrasynovial CD8+ T cells which could modulate their cytotoxicity and play a role in the control of this HLA class I-associated autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978777     DOI: 10.1093/intimm/14.5.471

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

1.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

Review 2.  [Role of innate receptors in chronic inflammation and autoimmunity].

Authors:  Marina Babic; Chiara Romagnani
Journal:  Z Rheumatol       Date:  2022-04-07       Impact factor: 1.530

3.  Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations.

Authors:  Carlos Lopez-Larrea; Miguel Angel Blanco-Gelaz; Juan Carlos Torre-Alonso; Jacome Bruges Armas; Beatriz Suarez-Alvarez; Laura Pruneda; Ana Rita Couto; Segundo Gonzalez; Antonio Lopez-Vázquez; Jesus Martinez-Borra
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

4.  Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.

Authors:  Alberto Bergamini; Maria Sole Chimenti; Eleonora Baffari; Maria Domenica Guarino; Gianfranco Gigliucci; Carlo Perricone; Roberto Perricone
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

5.  Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis.

Authors:  Christina Duftner; Christian Goldberger; Albrecht Falkenbach; Reinhard Würzner; Barbara Falkensammer; Karl P Pfeiffer; Elisabeth Maerker-Hermann; Michael Schirmer
Journal:  Arthritis Res Ther       Date:  2003-07-16       Impact factor: 5.156

6.  Activation-Induced Killer Cell Immunoglobulin-like Receptor 3DL2 Binding to HLA-B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis.

Authors:  Anna Ridley; Hiroko Hatano; Isabel Wong-Baeza; Jacqueline Shaw; Katherine K Matthews; Hussein Al-Mossawi; Kristin Ladell; David A Price; Paul Bowness; Simon Kollnberger
Journal:  Arthritis Rheumatol       Date:  2016-04       Impact factor: 10.995

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.